Zanubrutinib for the treatment of chronic lymphocytic leukemia

Expert Opin Pharmacother. 2023 Sep-Dec;24(13):1409-1413. doi: 10.1080/14656566.2023.2229734. Epub 2023 Jun 26.

Affiliations

¹ Hematology Unit, Azienda Ospedaliera Annunziata, Cosenza, Italy.
² Scientific Directorate IRCCS of Reggio Emilia, Reggio Emilia, Italy.
³ Biotechnology Research Unit, AO of Cosenza, Cosenza, Italy.
⁴ Department of Pharmacy, Health and Nutritional Science, University of Calabria, Rende, Italy.

PMID: 37350553
DOI: 10.1080/14656566.2023.2229734

No abstract available

Keywords: BTKi; CLL; Zanubrutinb; precision medicine; therapy.

Publication types

Editorial

MeSH terms

Humans
Leukemia, Lymphocytic, Chronic, B-Cell* / drug therapy
Piperidines / therapeutic use
Protein Kinase Inhibitors / adverse effects
Pyrazoles / adverse effects
Pyrimidines / adverse effects

Substances

zanubrutinib
Pyrazoles
Pyrimidines
Piperidines
Protein Kinase Inhibitors